

Press release

Contact:

Torben Jörgensen, President and CEO

Tel: +46 707 49 05 84, torben.jorgensen@eu.biotage.com

Biotage AB

Kungsgatan 76

SE-753 18 Uppsala

Tel+46 18 56 59 00

www.biotage.com

Uppsala March 29, 2008

NOTICE OF ANNUAL GENERAL MEETING IN BIOTAGE AB

Shareholders in Biotage AB are hereby invited to attend the Annual General Meeting, to be held on Tuesday, April 29, 2008, at 4.00 p.m., at the head office of Biotage AB, Kungsgatan 76 in Uppsala, Sweden.

Notice etc.

Shareholders who wish to participate in the General Meeting must

- a) be recorded as a shareholder in the share register maintained by VPC on Wednesday, April 23, 2008, and
- b) notify the company of their intention to participate in the General Meeting, no later than Friday, April 25, 2008, at 4.00 p.m.

Notice of participation in the General Meeting may be made to the company by mail to the address Kungsgatan 76, SE-753 18 Uppsala, Sweden, by fax + 46-18-591922, by telephone + 46-18-565900 or by e-mail: deltagare@eu.biotage.com. The notification should include the following information: name, social security number/corporate registration number, address, telephone number, shareholdings and number of accompanying assistants (maximum two).

Shareholders participating through a representative must provide a proxy for the representative. If the proxy is issued by a legal entity, a certified copy of the registration certificate for the legal entity must be enclosed. The proxy may not be older than one year. The proxy in the original and, where applicable, the registration certificate should be sent in due time prior to the General Meeting, to Biotage AB at the address Kungsgatan 76, 753 18 Uppsala, Sweden.

To be entitled to participate in the General Meeting, shareholders whose shares are nominee registered must temporarily have the shares owner-registered with VPC. Shareholders who wish to make such re-registration must notify their nominee thereof. The re-registration must be made no later than on Wednesday, April 23, 2008, and the shareholders should in due time before such date notify the nominee thereof.

Number of shares and votes

In the company there are in total 88,486,320 shares with one vote each.

Proposed Agenda

1. Opening of the General Meeting and election of the Chairman.
2. Preparation and approval of the voting list.
3. Approval of the agenda.
4. Election of two persons to approve the minutes.
5. Determination whether the General Meeting has been duly convened.
6. Presentation of the annual report and the auditors report, as well as the consolidated accounts and the auditors report on the consolidated accounts.
7. Presentation of the work of the Board of Directors during the past year.
8. Speech by the CEO.
9. Resolutions on approval of the income statement and the balance sheet, and the consolidated income statement and the consolidated balance sheet.
10. Resolution on allocation of the company's profit or loss pursuant to the approved balance sheet.
11. Resolution on discharge from liability for the Board members and the CEO.
12. Resolution on the number of Board members and deputy Board members to be elected by the General Meeting.

13. Resolution on the fees payable to the Board of Directors and the auditors.
14. Election of Board members and potential deputy Board members as well as Chairman of the Board of Directors.
15. Election of Auditors
16. Resolution on the Nomination Committee.
17. Resolution on guidelines for compensation for the executive management.
18. Resolution on authorization for the Board of Directors to issue shares and/or convertibles.
19. Closing of the General Meeting.

Item 10 - Proposal for resolution on the appropriation of earnings

The Board of Directors and the Managing Director propose that the accumulated losses amounting to 667,6 MSEK shall be covered by reducing the statutory reserve with the equivalent amount.

Items 1 and 12 to 15 – Election of Chairman at the General Meeting, resolution on the number of Board members and deputy Board members to be elected by the General Meeting, resolution on fees payable to the Board of Directors and auditors and election of Board members and potential deputy Board members as well as Chairman of the Board of Directors

The Nomination Committee of Biotage AB, consisting of Karl Swartling (Investor Growth Capital), Björn Odlander (HealthCap), Carl Rosén (2 AP-fonden) and Ove Mattsson, Chairman of the Board of Directors, proposes the following:

- Ove Mattsson shall be elected Chairman of the Meeting.
 - Nine Board members (with no deputy Board members) shall be elected.
 - A fixed fee of SEK 1,400,000 shall be determined for the period up to and including the Annual General Meeting 2009 to be distributed as follows: the Chairman shall receive SEK 400,000 and each of the other Board members elected by the General Meeting who are not employed by the company shall receive SEK 125,000. In addition to that, a fee shall be paid to the members of the Auditing Committee of an aggregate of not more than SEK 100,000, whereof the Chairman shall receive SEK 50,000 and the other members SEK 25,000 each.
 - Fees payable to the auditors for the period up to and including the Annual General Meeting 2009 shall, as before, be paid against approved account.
 - Re-election of the current Board of Directors, i.e. Anders Rydin, Thomas Eklund, Annika Espander, Staffan Lindstrand, Ove Mattsson, Bengt Samuelsson, Mathias Uhlén, Axel Broms and Per-Olof Eriksson. Ove Mattsson is proposed to be re-elected as Chairman of the Board of Directors.
 - Election of Deloitte AB, with Marcus Sörlander as auditor in charge, as the company's auditor for the period until the end of the General Meeting held 2012.
- Shareholders together representing more than 38 per cent of the voting rights in the company have declared that they intend to vote in favour of the above proposals for resolutions.

Items 16 - Resolution on the Nomination Committee

Shareholders together representing more than 38 per cent of the voting rights in the company propose that the General Meeting resolves as follows: the Chairman of the Board of Directors shall be elected member of the Nomination Committee and shall be instructed to appoint, in consultation with the (by voting rights) major shareholders of the company as per September 1, 2008, another three members. The names of such members shall be published no later than six months before the Annual General Meeting 2009. The Nomination Committee shall appoint one of the members to be the Chairman of the Nomination Committee. The Chairman of the Board of Directors shall not be appointed as Chairman of the Nomination Committee.

In case a shareholder, whom a member of the Nomination Committee represents, is no longer one of the (by voting rights) major shareholders of the company, or if a member of the Nomination Committee is no longer employed by such shareholder or for any other reason leaves the Nomination Committee before the Annual General Meeting 2009, the other members of the Nomination Committee shall jointly have the right to appoint another representative of the major shareholders to replace such member.

The Nomination Committee shall, before the Annual General Meeting 2009, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual General Meeting, the determination of fees and matters pertaining thereto.

Item 17 - Resolution on guidelines for compensation for the executive management

The Board of Directors' proposal regarding guidelines for compensation for the executive management

The company shall strive to offer members of the executive management of the company a compensation that is adjusted to the conditions of the market. The Compensation Committee shall prepare and present such compensation proposals to the Board of Directors for resolution. In the compensation proposals the importance of the work, competence, experience and performance shall be taken into account. The compensation may consist of: fixed yearly income, variable income, pension benefits, discretionary bonus arrangements, and severance pay. The Board of Directors may for certain special purposes, if it is motivated by special circumstances, choose to deviate from these guidelines.

Item 18 - Resolution on authorization for the Board of Directors to issue shares and/or convertibles

The Board of Directors proposes that the General Meeting adopts a resolution to authorize the Board of Directors to, until the Annual General Meeting 2009, at one or several occasions and with or without deviation from the shareholders' preferential rights, adopt resolutions to issue shares and/or convertibles. The Board of Directors shall have the right to resolve that the shares and/or the convertibles shall be paid in kind or otherwise be subject to conditions referred to in Chapter 2 Section 5 second paragraph 1-3 and 5 of the Swedish Companies Act or that the shares and/or the convertibles shall be subscribed for with a right of set-off. The Board of Directors resolutions to issue shares and/or convertibles may result in an increase of the number of shares in the company of not more than 8,800,000 shares, in the aggregate (assuming full conversion of the convertibles and before any re-calculations according to the conditions of the convertibles). Issues may be made in order to finance acquisitions of companies or parts of companies, or to strengthen the company's capital base and equity/assets ratio in case a situation would occur when the company, in the opinion of the Board of Directors, is in need of a rapid contribution of equity. In case of a directed cash issue of shares, the subscription price for the new shares shall be determined in close connection with the share price for the Biotage share on the Stockholm Stock Exchange at the time of the issue. In case of a directed cash issue of convertibles, the pricing and conditions of the convertibles shall be in line with market conditions. Considering the above, the Board of Directors shall also be authorized to resolve on such other conditions that the Board of Directors finds necessary to carry out the issues. The reasons for the right to deviate from the shareholders preferential rights are to enable the company to, in a quick and effective way, finance company acquisitions or through a directed issue strengthen the company's capital base and equity/assets ratio. In case of full exercise of the authorization, and assuming full conversion of any issued convertibles (however before any re-calculations according to the conditions of the convertibles), the dilution effect corresponds to approximately 9 per cent of the share capital and the votes.

The Board of Directors, or any person appointed by the Board of Directors, shall be authorized to make minor adjustments of the resolution adopted by the General Meeting in order to fulfil the registration with the Swedish Companies Registration Office (Sw. Bolagsverket). A resolution by the General Meeting to adopt the Board of Directors' proposal shall be valid only where shareholders holding no less than two thirds of the votes cast as well as the shares represented at the General Meeting approve the resolution.

Documents

The accounting documents and the Auditor's report and the complete proposal for the resolution under item 17 above together with the Auditor's report in accordance with Chapter 8 Section 54 of the Swedish Companies Act will be held available at the company at the address Kungsgatan 76 in Uppsala as from Tuesday, April 15, 2008. The above documents will also be sent to shareholders upon request and will also be available on the company's website www.biotage.com and at the General Meeting. A proxy form is available at www.biotage.com/fullmakt

Uppsala in March 2008
Biotage AB (publ)
The Board of Directors

About Biotage

Biotage is a global company active in life science research with strong technologies, a broad range of operations and a long-term view of the market. The company offers solutions, knowledge and experience in the areas of genetic analysis and medicinal chemistry. In 2005 operations and products were acquired from the American company Argonaut, further strengthening the medicinal chemistry product range. The customers include the worlds top 30 pharmaceutical companies, the worlds top 20 biotech companies, and leading academic institutes. The company is headquartered in Uppsala and has offices in the U.S., Japan, UK, Germany and several other European countries. Biotage has 320 employees and had sales of 496,4 MSEK in 2007. Biotage is listed on the OMX Nordic Exchange Stockholm AB. Website: www.biotage.com